Upgrade to SI Premium - Free Trial

Rhythm Pharmaceuticals (RYTM) PT Raised to $160 at Citizens on Imcivree Launch

August 5, 2026 4:19 AM
Citizens analyst Jonathan Wolleben raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $160.00 (from $155.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change